Biosimilar Litigation and Related Patents Analysis

• Main Authors: Zih-Sian Yu, 余子弦
• Other Authors: Chun-Shan Chen
• Format: Others
• Language: zh-TW
• Published: 2019
• Online Access: http://ndltd.ncl.edu.tw/handle/mu2y4q

碩士 === 國立臺北科技大學 === 智慧財產權研究所 === 107 === In recent years, the research and development of drugs had become more difficult to explore and develop breakthrough small molecule drugs. Biosimilar drugs had lower breakage rate and higher successful yield in the development of new drugs, so many pharmaceutical companies had turned to the development of biosimilar. In the economic aspect of drug research and development, or for a huge market of biosimilar markets, biosimilar could maintain huge profits even if the price was lower than the biological product, attracting many pharmaceutical companies to invest and develop biosimilar, even included the multinational large pharmaceutical companies that develop new drugs. This paper is an introduction to the definition and litigation of biosimilar and researched on subject-related legal proceedings. Used the index to Analysis the biosimilar patents. According to the results of patent analysis, understood the strength of patents, the future development direction of technology and the litigation layout of cases to provide the direction for the future development of manufacturers.